Eurofins CDMO Alphora Inc. Relocates, Expands In Canada

Sheridan Research Park in Mississauga, Ontario is the new home of the company’s API process R&D activity, solid-state R&D activity and analytical services team.

Eurofins CDMO Alphora Inc. has relocated and expanded its API development laboratories from 2395 Speakman Drive to a new facility within the Sheridan Research Park in Mississauga, Ontario, Canada.

The 56,000-square-foot building is the new home of the company’s API process R&D activity, solid-state R&D activity, and its analytical services team. The state-of-the-art laboratory facility includes 26 fume hoods supporting Process R&D; a 50L scale Kilo laboratory equipped with 6 walk-in fume hoods; cGMP Analytical Services; HPAPI development laboratories; a new Bruker 400 mHz NMR; as well as offices for employees and client meetings. The new facility expands capacity to support the continued growth of client programs and offers new Kilo Laboratory services for larger quantities of preclinical materials for toxicological studies.

(Photo: Business Wire)

The new site fits into Eurofins CDMO Alphora’s vision for its 14-acre campus located over two nearly adjacent sites within the Sheridan Research Park, establishing a suite of complementary and integrated service offerings to support biopharmaceutical development.

The new Hadwen API development laboratories are located nearly opposite the corporate site, which also houses drug product development and manufacturing, quality assurance, the newly completed 100L scale GMP HPAPI facility (2022), and a 2000L scale GMP API plant (operational mid-2023). The campus is also within 2.5 km of Eurofins CDMO Alphora Inc.’s existing API production facility.

Manitoba To Invest Up To $40M In CentrePort South ExpansionCanada

Located in the City of Winnipeg, CentrePort Canada is North America’s largest tri-modal inland port and foreign trade zone. Read more…

This latest addition is another important step towards Eurofins CDMO Alphora’s vision to build out its Sheridan Research Park campus with additional capacity and technologies in CDMO and biopharmaceutical services.